Manufacturing
-
A Multiple Target Approach To Universal Influenza Vaccine Development
9/7/2022
With a unique multi-target approach, what it considers the world's best adjuvant, and a host of learnings from the successes and failures of COVID-19 vaccine efforts, Longhorn Vaccines & Diagnostics is gaining steam in its pursuit of a universal influenza vaccine. On this episode of the Business of Biotech, Longhorn Vaccines Co-Founder and President Jeff Fischer gives us a transparent look at the science and the partnerships that are giving him cause to believe his company will succeed where so many have failed.
-
Propagating Peptides With Peptilogics' Jonathan Steckbeck, Ph.D.
5/24/2023
Peptilogics CEO and founder Dr. Jonathan Steckbeck walks us through his transition from academic work into a clinical-stage company, how he's sustaining the company in a lean capital market, and more.
-
Cell Therapy Platform Dev With Precigen CEO Dr. Helen Sabzevari
3/29/2021
Learn how Precigen is advancing a deep pipeline of immuno-oncology, infectious disease, and autoimmune disorder candidates through the clinic on the back of its UltraCAR-T platform. CEO Dr. Helen Sabzevari describes the promise of the platform to change the CAR T complexity paradigm with an overnight manufacturing process to affect patients in urgent need of timely therapy.
-
Foundations Of Flexible Manufacturing With Sarepta Therapeutics' Brian Winstead
11/1/2021
Is "flexible manufacturing" just another empty buzz concept concocted by the biopharma equipment marketing community, or does it demonstrate real benefit to bioprocess pros and their companies? On this episode, we sit down with Sarepta Therapeutics Director of Pharmaceutical Engineering Brian Winstead and Project Farma VP Tony Khoury to discuss what flexible manufacturing means, where it works, and where it doesn't. Listen in as Winstead shares the flexible manufacturing philosophy at Sarepta.
-
Women In Biotech With Bill & Melinda Gates MRI's Piper Trelstad, Ph.D.
1/16/2023
After more than 21 years leading process, product, and technical development efforts at Merck and Takeda, Piper Trelstad, Ph.D. joined the Bill & Melinda Gates Medical Research Institute (MRI) in January 2022. On this episode of the Business of Biotech, we'll dive into how the MRI, a full-fledged clinical-stage biopharmaceutical company, is tackling health problems that challenge some of the world's most vulnerable populations. Dr. Trelstad also shares her minority perspective as a woman working in a highly technical capacity in biopharma, and how the industry can proactively support and advance women in technical roles.
-
Solving The COVID-19 Workforce Crisis
8/13/2020
Obsidian Therapeutics CEO Dr. Paul Wotton didn't let pandemic-induced workforce restrictions impede his biopharma's progress. Instead, his team developed a software system purpose-built for biotechs to manage personnel and equipment per ever-changing guidelines. On this episode of The Business Of Biotech: Summer Executive Sessions, Wotton tells us how the application, dubbed SWIFT, was built, how it's working, and why Obsidian has made it available to more than 30 (and growing) other biotechs, free of charge.
-
Cold Chain Integrity & Sustainability With Celyad Oncology's Thomas Lequertier
8/18/2021
Maintaining therapeutic integrity through cryopreservation and super cold supply chains have challenged, and continue to vex, biologics producers. On this episode of the Business of Biotech, Celyad Oncology Head of Cell Therapy Manufacturing Thomas Lequertier shares best practices for the cryopreservation of cell therapies while minimizing cell degradation, maintaining their integrity on the journey from the lab to the patient, and what the future holds for cold chain biologic therapy logistics.
-
Filling A Vaccine Void With Cue Biopharma's Dan Passeri, J.D.
4/18/2021
CUE Biopharma CEO Dan Passeri, J.D. joins us for a discussion on the development of the company's Immuno-STAT platform for the selective targeting and alteration of T cells. Passeri shares the rationale behind his belief in the company's immunotherapeutic approach, and how the CUE-100 series of candidates in its pipeline are being developed to address a scourge of HPV-related head, neck, and other cancers.
-
A More NIIMBL Biotech Workforce With John Balchunas
5/4/2023
What are biopharma's greatest skilled manufacturing labor needs, and what's the industry doing to fill them? John Balchunas is on the front lines in his position as Workforce Director at NIIMBL, the National Institute for Innovation in Manufacturing Biopharmaceuticals, and he says advanced degrees and pedigrees aren't the answer. The breadth and depth of NIIMBL's efforts to influence the next generation of the biopharma workforce — from high school vocational programs to community colleges and on-the-job development—might surprise you. Listen in as Balchunas brings the Business of Biotech up to speed on a training and development agenda that plants seeds early and often.
-
The CDMO Capacity Crunch ft. Discovery Labs' Audrey Greenberg And Iovance Biotherapeutics' Sumit Verma
10/27/2021
While nary a day goes by without a shovel breaking ground on a new CDMO buildout, biopharmas remain hard-pressed to secure the outsourced manufacturing space and expertise needed to meet timelines, satisfy investors, and drive competitive advantage. On this episode of the Business of Biotech, we're tackling the CDMO capacity crunch from every angle in a spirited discussion with Discovery Labs & Center for Breakthrough Medicines Co-Founder Audrey Greenberg, Iovance SVP of Commercial Manufacturing Sumit Verma, and Project Farma CEO Anshul Mangal.